High Tumour Cannabinoid CB1 Receptor Immunoreactivity Negatively Impacts Disease-Specific Survival in Stage II Microsatellite Stable Colorectal Cancer
Author Information
Author(s): Gustafsson Sofia B., Palmqvist Richard, Henriksson Maria L., Dahlin Anna M., Edin Sofia, Jacobsson Stig O. P., Öberg Åke, Fowler Christopher J.
Primary Institution: Umeå University, Sweden
Hypothesis
Is CB1 receptor immunoreactivity associated with disease severity and outcome in colorectal cancer?
Conclusion
A high level of CB1 receptor expression in colorectal cancer is linked to poorer prognosis in stage II microsatellite stable patients.
Supporting Evidence
- High CB1 receptor expression is associated with poorer disease-specific survival in stage II microsatellite stable colorectal cancer patients.
- Patients with CB1IR≥2 had significantly lower 5-year event-free survival probabilities compared to those with CB1IR<2.
- CB1 receptor immunoreactivity was assessed in a large cohort of colorectal cancer cases.
Takeaway
This study found that higher levels of a specific receptor in colorectal cancer are linked to worse survival rates for some patients.
Methodology
CB1 receptor immunoreactivity was assessed in tumor samples from colorectal cancer patients, and its association with disease outcomes was analyzed using statistical methods.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific patient population analyzed.
Limitations
The study's findings may not be generalizable to all colorectal cancer patients due to the specific focus on microsatellite stable tumors.
Participant Demographics
Median age was 71 years, with 269 males and 218 females; cancer locations included right colon (31.1%), left colon (31.1%), and rectum (37.8%).
Statistical Information
P-Value
p<0.005
Confidence Interval
95% CI 0.40–0.91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website